The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Kristina S BoyeJérémie LebrecAnne DibElke HeitmannMarco Orsini FedericiMaria YuHélène SapinAnnabel BarrettBruno GuerciFrancesco GiorginoMartin FüchtenbuschLuis-Emilio Garcia-PerezPublished in: Diabetes, obesity & metabolism (2023)
Improvements in PROs observed in TROPHIES, which were more evident with dulaglutide than liraglutide, reflect a relevant clinical benefit. From the patients' perspective, satisfaction, and confidence in continuing treatment with GLP-1RAs is likely to contribute to long-term treatment persistence.